CorMedix

IPO

Home - CorMedix | Prevention of cardiac, renal and infectious diseases

Public · Berkeley Heights, United States · Founded 2006 · $150.0M raised

Founded
2006
Business Model
B2B
Total Funding
$150.0M
Last Round
$150.0M Convertible NoteAug 2025
Rounds
1
Type
Public

About

CorMedix (now CorMedix Therapeutics, NASDAQ: CRMD) is a biopharmaceutical company founded in 2006 and headquartered in Berkeley Heights, New Jersey. The company focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases, including its lead product DefenCath (taurolidine/heparin), an FDA-approved catheter lock solution. In 2025, CorMedix acquired Melinta Therapeutics, significantly expanding its commercial antibiotic portfolio.

Summary

CorMedix is a Biotech company based in Berkeley Heights, United States, founded in 2006. It has raised $150.0M in total across 1 round, most recently a $150.0M Convertible Note round in Aug 2025. Investors include Deerfield Management.

Tech & App Stack

5 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

ConvertibleConvertible NoteAug 2025
$150.0M

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

CorMedix on Indexed.vc
<a href="https://indexed.vc/companies/cormedix"><img src="https://indexed.vc/api/badge/company/cormedix" alt="CorMedix on Indexed.vc" width="260" height="76" /></a>